Pyk2与肿瘤关系的研究进展
|
摘要
富含脯氨酸蛋白酪氨酸激酶(Pyk2)是黏着斑激酶家族中的一员。Pyk2参与包括乳腺癌、肝癌在内的多种肿瘤的发生、浸润及转移,并且与肿瘤的预后密切相关。明确Pyk2在肿瘤发生发展中的作用,能为新的抗癌靶向药物的研发提供理论基础。
Proline-rich protein tyrosine kinase(Pyk2) is a member of the focal adhesion kinase family. Pyk2 is involved in the occurrence, invasion and metastasis of various tumors, including breast and hepatic cancer. It's also closely related to the prognosis of tumors. To clarify the role of Pyk2 in tumorigenesis and development can provide a theoretical basis for the creation of new anti-cancer targeted drugs.
Proline-rich protein tyrosine kinase(Pyk2) is a member of the focal adhesion kinase family. Pyk2 is involved in the occurrence, invasion and metastasis of various tumors, including breast and hepatic cancer. It's also closely related to the prognosis of tumors. To clarify the role of Pyk2 in tumorigenesis and development can provide a theoretical basis for the creation of new anti-cancer targeted drugs.
引文
[1] Raab M, Lu Y, Kohler K, et al. LFA-1 activates focal adhesion kinases FAK1/PYK2 to generate LAT-GRB2-SKAP1 complexes that terminate T-cell conjugate forma-tion [J]. Nat Commun, 2017, 8:16001.doi: 10.1038/ncomms16001.
[2] Canobbio I, Cipolla L, Guidetti GF, et al. The focal adhesion kinase Pyk2 links Ca2+ signalling to Src family kinase activation and protein tyrosine phosphorylation in thrombin-stimulated platelets [J]. Biochem J, 2015, 469: 199-210.
[3] Eleniste PP, Patel V, Posritong S, et al. Pyk2 and megakaryocytes regulate osteoblast differentiation and migration via distinct and overlapping mechanisms [J]. J Cell Biochem, 2016, 117: 1396-1406.
[4] Narendra Talabattula VA, Morgan P, Frech MJ, et al. Non-canonical pathway induced by Wnt3a regulates beta-catenin via Pyk2 in differentiating human neural progenitor cells [J]. Biochem Biophys Res Commun, 2017, 491: 40-46.
[5] Kedan A, Verma N, Saroha A, et al. PYK2 negatively regulates the Hippo pathway in TNBC by stabilizing TAZ protein [J]. Cell Death Dis, 2018, 9: 985. doi: 10.1038/s41419-018-1005-z.
[6] Verma N, Keinan O, Selitrennik M, et al. PYK2 sustains endosomal-derived receptor signalling and enhances epithelial-to-mesenchymal transition [J]. Nat Commun, 2015, 6:6064.doi: 10.1038/ncomms7064.
[7] Genna A, Lapetina S, Lukic N, et al. Pyk2 and FAK differentially regulate invadopodia formation and function in breast cancer cells [J]. J Cell Biol, 2018, 217: 375-395.
[8] Verma N, Muller AK, Kothari C, et al. Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4-NDRG1 axis [J]. Cancer Res, 2017, 77: 86-99.
[9] Gong J, Luk F, Jaiswal R, et al. Microparticles mediate the intercellular regulation of microRNA-503 and proline-rich tyrosine kinase 2 to alter the migration and invasion capacity of breast cancer cells [J]. Front Oncol, 2014, 4:220.doi: 10.3389/fonc.2014.00220.
[10] Sun CK, Ng KT, Lim ZX, et al. Proline-rich tyrosine kinase 2 (Pyk2) promotes cell motility of hepatocellular carcinoma through induction of epithelial to mesenchymal transition [J]. PLoS One, 2011, 6: e18878.doi: 10.1371/journal.pone.0018878.
[11] Geng W, Ng KT, Sun CK, et al. The role of proline rich tyrosine kinase 2 (Pyk2) on cisplatin resistance in hepatocellular carcinoma [J]. PLoS One, 2011, 6: e27362. doi: 10.1371/journal.pone.0027362.
[12] Cao J, Liu J, Long J, et al. microRNA-23b suppresses epithelial-mesenchymal transition (EMT) and metastasis in hepatocellular carcinoma via targeting Pyk2 [J]. Biomed Pharmacother, 2017, 89:642-650.
[13] Ding Z, Dhruv H, Kwiatkowska-Piwowarczyk A, et al. PDZ-RhoGEF is a signaling effector for TROY-induced glioblastoma cell invasion and survival [J]. Neoplasia, 2018, 20: 1045-1058.
[14] Rolon-Reyes K, Kucheryavykh YV, Cubano LA, et al. Microglia activate migration of glioma cells through a Pyk2 intracellular pathway [J]. PLoS One, 2015, 10: e0131059. doi: 10.1371/journal.pone.0131059.
[15] Loftus JC, Yang Z, Kloss J, et al. A novel interaction between Pyk2 and MAP4K4 is integrated with glioma cell migration [J]. J Signal Transduct, 2013, 2013:956580. doi: 10.1155/2013/956580.
[16] Xu CS, Wang ZF, Dai LM, et al. Induction of proline-rich tyrosine kinase 2 activation-mediated C6 glioma cell invasion after anti-vascular endothelial growth factor therapy [J]. J Transl Med, 2014, 12:148.doi: 10.1186/1479-5876-12-148.
[17] Aguilera KY, Huang H, Du W, et al. Inhibition of discoidin domain receptor 1 reduces collagen-mediated tumorigenicity in pancreatic ductal adenocarcinoma [J]. Mol Cancer Ther, 2017, 16: 2473-2485.
[18] Huang H, Svoboda RA, Lazenby AJ, et al. Up-regulation of N-cadherin by collagen Ⅰ-activated discoidin domain receptor 1 in pancreatic cancer requires the adaptor molecule Shc1 [J]. J Biol Chem, 2016, 291: 23208-23223.
[19] Gao C, Chen G, Kuan SF, et al. FAK/PYK2 promotes the Wnt/beta-catenin pathway and intestinal tumorigenesis by phosphorylating GSK3 beta [J]. eLife, 2015, 4.doi: 10.7554/eLife.10072.
[20] Pasquier J, Gosset M, Geyl C, et al. CCL2/CCL5 secreted by the stroma induce IL-6/PYK2 dependent chemoresistance in ovarian cancer [J]. Mol Cancer, 2018, 17: 47. doi: 10.1186/s12943-018-0787-z.
[21] Wiese H, Gelis L, Wiese S, et al. Quantitative phosphoproteomics reveals the protein tyrosine kinase Pyk2 as a central effector of olfactory receptor signaling in prostate cancer cells [J]. Biochim Biophys Acta, 2015, 1854: 632-640.
[22] Zhao T, Bao Y, Lu X, et al. Pyk2 promotes tumor progression in renal cell carcinoma [J]. Oncol Lett, 2018, 16: 5953-5959.
[2] Canobbio I, Cipolla L, Guidetti GF, et al. The focal adhesion kinase Pyk2 links Ca2+ signalling to Src family kinase activation and protein tyrosine phosphorylation in thrombin-stimulated platelets [J]. Biochem J, 2015, 469: 199-210.
[3] Eleniste PP, Patel V, Posritong S, et al. Pyk2 and megakaryocytes regulate osteoblast differentiation and migration via distinct and overlapping mechanisms [J]. J Cell Biochem, 2016, 117: 1396-1406.
[4] Narendra Talabattula VA, Morgan P, Frech MJ, et al. Non-canonical pathway induced by Wnt3a regulates beta-catenin via Pyk2 in differentiating human neural progenitor cells [J]. Biochem Biophys Res Commun, 2017, 491: 40-46.
[5] Kedan A, Verma N, Saroha A, et al. PYK2 negatively regulates the Hippo pathway in TNBC by stabilizing TAZ protein [J]. Cell Death Dis, 2018, 9: 985. doi: 10.1038/s41419-018-1005-z.
[6] Verma N, Keinan O, Selitrennik M, et al. PYK2 sustains endosomal-derived receptor signalling and enhances epithelial-to-mesenchymal transition [J]. Nat Commun, 2015, 6:6064.doi: 10.1038/ncomms7064.
[7] Genna A, Lapetina S, Lukic N, et al. Pyk2 and FAK differentially regulate invadopodia formation and function in breast cancer cells [J]. J Cell Biol, 2018, 217: 375-395.
[8] Verma N, Muller AK, Kothari C, et al. Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4-NDRG1 axis [J]. Cancer Res, 2017, 77: 86-99.
[9] Gong J, Luk F, Jaiswal R, et al. Microparticles mediate the intercellular regulation of microRNA-503 and proline-rich tyrosine kinase 2 to alter the migration and invasion capacity of breast cancer cells [J]. Front Oncol, 2014, 4:220.doi: 10.3389/fonc.2014.00220.
[10] Sun CK, Ng KT, Lim ZX, et al. Proline-rich tyrosine kinase 2 (Pyk2) promotes cell motility of hepatocellular carcinoma through induction of epithelial to mesenchymal transition [J]. PLoS One, 2011, 6: e18878.doi: 10.1371/journal.pone.0018878.
[11] Geng W, Ng KT, Sun CK, et al. The role of proline rich tyrosine kinase 2 (Pyk2) on cisplatin resistance in hepatocellular carcinoma [J]. PLoS One, 2011, 6: e27362. doi: 10.1371/journal.pone.0027362.
[12] Cao J, Liu J, Long J, et al. microRNA-23b suppresses epithelial-mesenchymal transition (EMT) and metastasis in hepatocellular carcinoma via targeting Pyk2 [J]. Biomed Pharmacother, 2017, 89:642-650.
[13] Ding Z, Dhruv H, Kwiatkowska-Piwowarczyk A, et al. PDZ-RhoGEF is a signaling effector for TROY-induced glioblastoma cell invasion and survival [J]. Neoplasia, 2018, 20: 1045-1058.
[14] Rolon-Reyes K, Kucheryavykh YV, Cubano LA, et al. Microglia activate migration of glioma cells through a Pyk2 intracellular pathway [J]. PLoS One, 2015, 10: e0131059. doi: 10.1371/journal.pone.0131059.
[15] Loftus JC, Yang Z, Kloss J, et al. A novel interaction between Pyk2 and MAP4K4 is integrated with glioma cell migration [J]. J Signal Transduct, 2013, 2013:956580. doi: 10.1155/2013/956580.
[16] Xu CS, Wang ZF, Dai LM, et al. Induction of proline-rich tyrosine kinase 2 activation-mediated C6 glioma cell invasion after anti-vascular endothelial growth factor therapy [J]. J Transl Med, 2014, 12:148.doi: 10.1186/1479-5876-12-148.
[17] Aguilera KY, Huang H, Du W, et al. Inhibition of discoidin domain receptor 1 reduces collagen-mediated tumorigenicity in pancreatic ductal adenocarcinoma [J]. Mol Cancer Ther, 2017, 16: 2473-2485.
[18] Huang H, Svoboda RA, Lazenby AJ, et al. Up-regulation of N-cadherin by collagen Ⅰ-activated discoidin domain receptor 1 in pancreatic cancer requires the adaptor molecule Shc1 [J]. J Biol Chem, 2016, 291: 23208-23223.
[19] Gao C, Chen G, Kuan SF, et al. FAK/PYK2 promotes the Wnt/beta-catenin pathway and intestinal tumorigenesis by phosphorylating GSK3 beta [J]. eLife, 2015, 4.doi: 10.7554/eLife.10072.
[20] Pasquier J, Gosset M, Geyl C, et al. CCL2/CCL5 secreted by the stroma induce IL-6/PYK2 dependent chemoresistance in ovarian cancer [J]. Mol Cancer, 2018, 17: 47. doi: 10.1186/s12943-018-0787-z.
[21] Wiese H, Gelis L, Wiese S, et al. Quantitative phosphoproteomics reveals the protein tyrosine kinase Pyk2 as a central effector of olfactory receptor signaling in prostate cancer cells [J]. Biochim Biophys Acta, 2015, 1854: 632-640.
[22] Zhao T, Bao Y, Lu X, et al. Pyk2 promotes tumor progression in renal cell carcinoma [J]. Oncol Lett, 2018, 16: 5953-5959.